What type of study is this?

This is a Meta-Analysis study (also classified as: Systematic Review).

What question did this study set out to answer?

This research aims to evaluate the efficacy and safety of fitusiran as a prophylactic treatment for haemophilia A and B.

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Systematic review shows fitusiran reduces bleeding in haemophilia A and B, indicating safety without increased adverse effects.

This research aims to evaluate the efficacy and safety of fitusiran as a prophylactic treatment for haemophilia A and B.
Conducted a systematic review under PRISMA guidelines
Included 6 RCTs with 438 participants
Analyzed data using Stata with pooled means and 95% confidence intervals
Assessed outcomes like annualised bleeding rate and quality of life indices
Evaluated safety outcomes for adverse effects
Fitusiran significantly reduced bleeding episodes across multiple endpoints
Notable decrease in annualised bleeding rate by 3.45, annualised joint bleeding rate by 2.19
Improvements in Haem-A-QoL total score detected
No significant increase in adverse effects or thromboembolic complications observed

Nasir et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark